We Speak Your Name Of Central Florida Inc.

We Speak Your Name Of Central Florida Inc., a woman-owned, Hispanic American-owned nonprofit organization based in Central Florida, operates exclusively as a federal grant sub-recipient, delivering social services programs funded through the Department of Health and Human Services Administration for Children and Families with no federal contract prime footprint.

The vendor's entire award portfolio consists of 14 sub-grant awards from the United States Conference of Catholic Bishops, the prime grantee on HHS/ACF programs. All fourteen sub-awards are tied to a single funding agency — the Department of Health and Human Services Administration for Children and Families — representing 100% of the vendor's federal exposure. The awards span from March 2024 through April 2025, with grant identifiers referencing programs designated as "SP II," "90ZU0631," and related ACF grant codes. Combined dollar value across all sub-awards is $490 thousand, with ten sub-awards in 2024 and four in the first quarter of 2025.

We Speak Your Name Of Central Florida holds no federal contract vehicle positions, no direct prime relationships with federal agencies, and no subcontract work under federal contracts. The vendor's role is entirely within the federal grant ecosystem as a sub-recipient of HHS/ACF funding distributed by the United States Conference of Catholic Bishops. The regular monthly award schedule — typically issued on the last day of each month from March 2024 through April 2025 — suggests a recurring funding stream for ongoing social services delivery rather than project-specific or episodic work.

The business profile as a tax-exempt woman-owned and Hispanic American-owned nonprofit aligns the vendor with federal grant programs prioritizing community-based organizations in underserved populations, but the source does not specify the concrete services delivered, target populations served, or grant program names corresponding to the code references. Activity remains flat (10 awards in 2024, 4 in the first four months of 2025), with no growth trajectory evident and no recompete risk given the sub-recipient structure and monthly funding cycle that does not mirror contract renewal patterns.